EPISODE · Sep 24, 2019 · 13 MIN
ANZUP 2019 Interviews - Andrew Weickhardt talks with Ian Davis about the ENZAMET study
from Talking Urology Podcast · host Talking Urology
In this ANZUP conference highlight, Andrew Weickhardt chats with Australia’s very own Ian Davis about ANZUP’s successful world leading phase 3 study, ENZAMET. Ian outlines ENZAMET for men with newly diagnosed metastatic hormone naïve prostate cancer and how it differs from the other trials involving second line anti-androgens in this space. Ian also discusses how you might decide between the myriad of treatment options that have now shown effect in the upfront hormone naïve metastatic setting.
What this episode covers
In this ANZUP conference highlight, Andrew Weickhardt chats with Australia’s very own Ian Davis about ANZUP’s successful world leading phase 3 study, ENZAMET. Ian outlines ENZAMET for men with newly diagnosed metastatic hormone naïve prostate cancer and how it differs from the other trials involving second line anti-androgens in this space. Ian also discusses how you might decide between the myriad of treatment options that have now shown effect in the upfront hormone naïve metastatic setting.
NOW PLAYING
ANZUP 2019 Interviews - Andrew Weickhardt talks with Ian Davis about the ENZAMET study
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Jan 2, 2026 ·47m
Dec 21, 2025 ·46m